BioSpace News Archive

Pharm Country

ENHERTU® Reduced the Risk of Disease Progression or Death by 72% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer

Detailed positive results from the head-to-head DESTINY-Breast03 phase 3 trial showed that ENHERTU®, the Daiichi Sankyo Company, Limited and AstraZeneca HER2 directed antibody drug conjugate, demonstrated superior progression-free survival versus trastuzumab emtansine, a HER2 directed ADC currently approved to treat patients with HER2 positive unresectable and/or metastatic breast cancer previously treated with trastuzumab and a taxane.

September 18, 2021
·
25 min read
Business

Personalis Receives New VA MVP Task Order and Record Quarterly Orders From Oncology Customers; Reconfirms Total Revenue Outlook for 2021 with Further Accelerated Oncology Growth

Personalis, Inc., a leader in advanced genomics for population sequencing and cancer, announced that the U.S. Department of Veterans Affairs Million Veteran Program has issued a new task order under its current contract with the company, with a value of up to approximately $10 million.

September 18, 2021
·
8 min read